Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

80%

4 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4

4(80.0%)

Phase 1

1(20.0%)

5Total

Phase 4(4)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT03218969Phase 1Completed

Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist

Role: lead

NCT05581576Phase 4Unknown

Pitolisant in Refractory Restless Legs Syndrome

Role: lead

NCT05529095Phase 4Unknown

Sublingual Apomorphine in Refractory Restless Legs Syndrome

Role: lead

NCT03229174Phase 4Completed

Brain Perfusion & Oxygenation in Parkinson's Disease With NOH

Role: lead

NCT02509793Phase 4Unknown

A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine)

Role: lead

All 5 trials loaded